2 results
Approved WMOWill not start
Primary ObjectivesPhase 1bConfirm the recommended CyPep-1 dose 20 mg every two weeks (Q2W) when administered by intratumoral (IT) injection in combination with pembrolizumab Phase 2aAssess the anti-tumor activity of CyPep-1 administered by IT…
Approved WMORecruiting
The purpose of this BIVV020 Phase 2 study is to determine the preliminary efficacy, safety, and tolerability of BIVV020 in three CIDP subpopulations including standard of care (SOC)-Treated, SOC-Refractory, and SOC-Naïve.